Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (UT1/UT2) Clinical Trial Not Allowed

National Institutes of Health

06 June 2025
For profit
Health, Justice and Social Welfare

This FOA provides support using the STTR cooperative agreement mechanisms for the development of novel extracellular vesicle-based therapeutic platforms for use in regenerative medicine. Both native and engineered EVs have demonstrated the ability for specific and targeted tissue and organ repair, which can be harnessed for applications such as extracellular vesicle-based therapeutics. The main objective for this funding opportunity is to support platform-oriented technology development associated with the production, manufacturing, and use, of extracellular vesicles as therapeutics in regenerative medicine.


Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. See full Notice of Funding Opportunity for additional details on eligibility.

Learn more or apply
All information about this funding has been collected from and belongs to the funding organization
21 April 2023